Contraception
Volume 82, Issue 2 , Pages 131-138 , August 2010

Endocrinological, metabolic and clinical features of treatment with oral contraceptive formulation containing ethinylestradiol plus chlormadinone acetate in nonobese women with polycystic ovary syndrome

  • Roberto Uras

      Affiliations

    • Department of Obstetrics and Gynaecology, University of Cagliari, 09124 Cagliari, Italy
    • ,
  • Marisa Orrù

      Affiliations

    • Department of Obstetrics and Gynaecology, University of Cagliari, 09124 Cagliari, Italy
    • ,
  • Fabiana Pani

      Affiliations

    • Department of Obstetrics and Gynaecology, University of Cagliari, 09124 Cagliari, Italy
    • ,
  • Maria Francesca Marotto

      Affiliations

    • Department of Obstetrics and Gynaecology, University of Cagliari, 09124 Cagliari, Italy
    • ,
  • Monica Pilloni

      Affiliations

    • Department of Obstetrics and Gynaecology, University of Cagliari, 09124 Cagliari, Italy
    • ,
  • Stefano Guerriero

      Affiliations

    • Department of Obstetrics and Gynaecology, University of Cagliari, 09124 Cagliari, Italy
    • ,
  • Rossella Etzi

      Affiliations

    • Department of Obstetrics and Gynaecology, University of Cagliari, 09124 Cagliari, Italy
    • ,
  • Pierina Zedda

      Affiliations

    • Department of Obstetrics and Gynaecology, University of Cagliari, 09124 Cagliari, Italy
    • ,
  • Roberto Sorge

      Affiliations

    • Laboratory of Biometry, University of Rome “Tor Vergata”, 00133 Roma, Italy
    • ,
  • Stefano Lello

      Affiliations

    • Department of Obstetrics and Gynaecology, University of Cagliari, 09124 Cagliari, Italy
    • ,
  • Gian Benedetto Melis

      Affiliations

    • Department of Obstetrics and Gynaecology, University of Cagliari, 09124 Cagliari, Italy
    • Corresponding Author InformationCorresponding author. Clinica Ginecologica Ostetrica e di Fisiopatologia della Riproduzione Umana del Dipartimento Chirurgico Materno-Infantile e di Scienze delle Immagini, Università degli Studi di Cagliari, Via Ospedale 46, 09124 Cagliari, Italy. Tel.: +39 070 652797; fax: +39 070 668575.
    • ,
  • Anna Maria Paoletti

      Affiliations

    • Department of Obstetrics and Gynaecology, University of Cagliari, 09124 Cagliari, Italy

Received 21 October 2009 ,Revised 5 January 2010 ,Accepted 27 January 2010.

References 

  1. Golland IM, Elstein ME. Results of an open one-year study with Diane-35 in women with polycystic ovarian syndrome. Ann N Y Acad Sci. 1993;687:263–271
  2. Falsetti L, Galbignani E. Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome. Contraception. 1990;42:611–619
  3. Vrbíková J, Cibula D. Combined oral contraceptives in the treatment of polycystic ovary syndrome. Hum Reprod Update. 2005;11:277–291
  4. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas. 2008;61:151–157
  5. Wiegratz I, Kutschera E, Lee JH, et al. Effect of four different oral contraceptives on various sex hormones and serum-binding globulins. Contraception. 2003;67:25–32
  6. Kuhl H, Jung-Hoffmann C. In: Pharmakologie der gestagene. Thieme: Kontrazeption; 1999;p. 28–31
  7. Druckmann R. Profile of the progesterone derivative chlormadinone acetate — pharmocodynamic properties and therapeutic applications. Contraception. 2009;79:272–281
  8. Schneider J, Kneip C, Jahnel U. Comparative effects of chlormadinone acetate and its 3alpha- and 3beta-hydroxy metabolites on progesterone, androgen and glucocorticoid receptors. Pharmacology. 2009;84:74–81
  9. Curran MP, Wagstaff AJ. Ethinylestradiol/chlormadinone acetate. Drugs. 2004;64:751–760
  10. Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas. 2003;46(Suppl 1):S7–S16
  11. Raudrant D, Rabe T. Progestogens with antiandrogenic properties. Drugs. 2003;63:463–492
  12. Bouchard P. Chlormadinone acetate (CMA) in oral contraception — a new opportunity. Eur J Contracept Reprod Health Care. 2005;10(Suppl 1):7–13
  13. Jung-Hoffmann C, Kuhl H. Divergent effects of two low-dose oral contraceptives on sex hormone-binding globulin and free testosterone. Am J Obstet Gynecol. 1987;156:199–203
  14. Schramm G, Steffens D. A 12-month evaluation of the CMA-containing oral contraceptive Belara: efficacy, tolerability and anti-androgenic properties. Contraception. 2003;67:305–312
  15. Schramm G, Heckes B. Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The Contraceptive Switch Study. Contraception. 2007;76:84–90
  16. Plewig G, Cunliffe WJ, Binder N, Höschen K. Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled Phase III trial. Contraception. 2009;80:25–33
  17. Uras R, Orrù M, Etzi R, et al. Evidence that in healthy young women, a six-cycle treatment with oral contraceptive containing 30 mcg of ethinylestradiol plus 2 mg of chlormadinone acetate reduces fat mass. Contraception. 2009;79:117–121
  18. Cagnacci A, Ferrari S, Tirelli A, Zanin R, Volpe A. Route of administration of contraceptives containing desogestrel/etonorgestrel and insulin sensitivity: a prospective randomized study. Contraception. 2009;80:34–39
  19. Winkler UH, Sudik R. The effects of two monophasic oral contraceptives containing 30 mcg of ethinyl estradiol and either 2 mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters. Contraception. 2009;79:15–23
  20. Paoletti AM, Cagnacci A, Soldani R, et al. Evidence that an altered prolactin release is consequent to abnormal ovarian activity in polycystic ovary syndrome. Fertil Steril. 1995;64:1094–1098
  21. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961;21:1440–1447
  22. Plewig G, Kligman A. In: Acne: morphogenesis and treatment. New York: Springer-Verlag; 1975;p. 162–163
  23. Kyle UG, Bosaeus I, De Lorenzo AD, et al. Bioelectrical impedance analysis-part II: utilization in clinical practice. Clin Nutr. 2004;23:1430–1453
  24. Martinoli R, Mohamed EI, Maiolo C, et al. Total body water estimation using bioelectrical impedance: a meta-analysis of the data available in the literature. Acta Diabetol. 2003;40(Suppl. 1):S203–S206
  25. Gudivaka R, Schoeller DA, Kushner RF, Bolt MJ. Single- and multifrequency models for bioelectrical impedance analysis of body water compartments. J Appl Physiol. 1999;87:1087–1096
  26. Paoletti AM, Cagnacci A, Depau GF, Orrù M, Ajossa S, Melis GB. The chronic administration of cabergoline normalizes androgen secretion and improves menstrual cyclicity in women with polycystic ovary syndrome. Fertil Steril. 1996;66:527–532
  27. Bonora E, Zavaroni I, Coscelli C, Butturini U. Decreased hepatic insulin extraction in subjects with mild glucose intolerance. Metabolism. 1983;32:438–446
  28. Polonsky KS, Rubenstein AH. C-peptide as a measure of the secretion and hepatic extraction of insulin. Pitfalls and limitations. Diabetes. 1984;33:486–494
  29. Morley JE, Patrick P, Perry HM. Evaluation of assays available to measure free testosterone. Metabolism. 2002;51:554–559
  30. Thomas L, Krebs CI. In: A review of statistical power analysis software. vol. 78:New York: Bulletin of the Ecological Society of America; 1997;p. 128–139
  31. Chassard D, Schatz B. The antigonadrotropic activity of chlormadinone acetate in reproductive women. Gynecol Obstet Fertil. 2005;33:29–34
  32. Murakoshi M, Ikeda R, Fukui N. The effects of chlormadinone acetate (CMA), antiandrogen, on the pituitary, testis, prostate and adrenal gland of the dog with spontaneous benign prostatic hyperplasia. J Toxicol Sci. 2001;26:119–127
  33. Térouanne B, Paris F, Servant N, Georget V, Sultan C. Evidence that chlormadinone acetate exhibits antiandrogenic activity in androgen-dependent cell line. Mol Cell Endocrinol. 2002;198:143–147
  34. Huang A, Brennan K, Azziz R. Prevalence of hyperandrogenemia in the polycystic ovary syndrome diagnosed by the National Institutes of Health 1990 criteria. Fertil Steril. 2009 Feb 25;[Epub ahead of print]
  35. Kumar A, Woods KS, Bartolucci AA, Azziz R. Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf). 2005;62:644–649
  36. Paoletti AM, Cagnacci A, Orrù M, Ajossa S, Guerriero S, Melis GB. Treatment with flutamide improves hyperinsulinemia in women with idiopathic hirsutism. Fertil Steril. 1999;72:448–453
  37. Holmäng A, Larsson BM, Brzezinska Z, Björntorp P. Effects of short-term testosterone exposure on insulin sensitivity of muscles in female rats. Am J Physiol. 1992;262(6 Pt 1):E851–E855
  38. Hennes MM, Shrago E, Kissebah AH. Receptor and postreceptor effects of free fatty acids (FFA) on hepatocyte insulin dynamics. Int J Obes. 1990;14:831–841
  39. Svedberg J, Strömblad G, Wirth A, Smith U, Björntorp P. Fatty acids in the portal vein of the rat regulate hepatic insulin clearance. J Clin Invest. 1991;88:2054–2058
  40. Geffner ME, Kaplan SA, Bersch N, Golde DW, Landaw EM, Chang RJ. Persistence of insulin resistance in polycystic ovarian disease after inhibition of ovarian steroid secretion. Fertil Steril. 1986;45:327–333
  41. Dunaif A, Green G, Futterweit W, Dobrjansky A. Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab. 1990;70:699–704
  42. Nader S, Riad-Gabriel MG, Saad MF. The effect of a desogestrel-containing oral contraceptive on glucose tolerance and leptin concentrations in hyperandrogenic women. J Clin Endocrinol Metab. 1997;82:3074–3077
  43. Godsland IF, Walton C, Felton C, Proudler A, Patel A, Wynn V. Insulin resistance, secretion, and metabolism in users of oral contraceptives. J Clin Endocrinol Metab. 1992;74:64–70
  44. Cagnacci A, Paoletti AM, Renzi A, et al. Glucose metabolism and insulin resistance in women with polycystic ovary syndrome during therapy with oral contraceptives containing cyproterone acetate or desogestrel. J Clin Endocrinol Metab. 2003;88:3621–3625
  45. Armstrong VL, Wiggam MI, Ennis CN, et al. Insulin action and insulin secretion in polycystic ovary syndrome treated with ethinyl oestradiol/cyproterone acetate. QJM. 2001;94:31–37
  46. Guido M, Romualdi D, Giuliani M, et al. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab. 2004;89:2817–2823

PII: S0010-7824(10)00042-9

doi: 10.1016/j.contraception.2010.01.022

Contraception
Volume 82, Issue 2 , Pages 131-138 , August 2010

Article Tools

* Image Usage & Resolution